Champalimaud Foundation

CF is a private non-profit organisation dedicated to research excellence in biomedical science. The Champalimaud Centre for the Unknown (CCU) is a state-of-the-art centre for basic and translational research, diagnosis and treatment of oncologic, neuropsychiatric and related diseases. Housing the Champalimaud Clinical Centre (CCC) and the Champalimaud Research (CR), CF provides a unique environment for cutting-edge research designed to reveal new knowledge and develop scientific solutions to medical problems. The CCC’s multidisciplinary teams focus their activity on the patient, offering care of excellence based on the most advanced technological means, with a focus on translational research in systems pathology and patient care in cancer and neuropsychiatry. Amongst the CCC’s multidisciplinary teams are the (i) Computational Clinical Imaging Group headed by Dr Nikolaos Papanikolaou, and the Imaging Department headed by Dr Celso Matos (member of the CR Direction Team). The AI work and research developed at these Units are at the interface between CCC and CR, promoting excellence in the clinical care that is delivered to patients, while it allows significant research advances in the respective fields.

Role of institution in the project

The Computational Clinical Imaging Group (CCIG) of Champalimaud Research will be working on developing radiomic signatures and AI models in prostate cancer including detection, characterization and risk of reccurence. In particular, CCIG researchers are planning to validate models that we have been trained in ProCancer-I (EU funded project) with the data of EUCAIM, related to improved detection of clinically significant disease and risk assessment of biochemical relapse after radical prostatectomy. In addition, CCIG will be involved on implementing dashboards to monitor data in the federated network of repositories providing expert software engineering knowledge.

Nikolaos Papanikolaou

Nikolaos Papanikolaou, PhD (Male), is a Principal Investigator in Oncologic Imaging and research group leader of the Computational Clinical Imaging Group in the Centre for the Unknown at Champalimaud Foundation, Lisbon, Portugal. Recently, he has appointed as the Machine Learning Imaging Lead for the AI Hub at Royal Marsden and recognized as an honorary reader at the Institute of Cancer Research, in London, UK. Dr. Nikolaos Papanikolaou studied biomedical engineering while he obtained his PhD from the Medical School of the University of Crete. He has published 120 scientific papers in peer-reviewed international journals and 20 chapters in international books. He has delivered more than 100 invited lectures at international congresses and educational courses. The main focus of his research is the development and validation of imaging biomarkers, radiomic signatures and AI models for cancer applications. He recently initiated the development of a Radiomics Network comprising luminary clinical sites in the US and Europe to advance research in that area of Radiomics. He is the section editor on AI, Radiomics, and Machine Learning in Cancer Imaging, and he is chairing the e-learning subcommittee of the International Cancer Imaging Society. He is the scientific coordinator of the Pro-Cancer-I project.

Celso Matos

Celso Matos studied medicine at the Medical School of the University of Brussels, Belgium and obtained his Medical Degree Magna Cum Laude in 1980. He became a Professor of Clinical Radiology in 2001 at Erasme University Hospital. In late 2015 Celso Matos moved to Lisbon to start his current position as Head of the Imaging Department and as co-Director of Champalimaud Research at the Champalimaud Foundation. Celso Matos has been President of the ESGAR in 2015-2017. He is also engaged in ESOR activities. His main focus is multidisciplinary research in pancreatic diseases and validation of Imaging Biomarkers for the prediction of response to cancer treatment. Celso Matos has (co) authored over 100 peer-reviewed articles and authored over 10 book chapters. He has been part of the Abdominal Section of the European Radiology Editorial Board and has been appointed Associate Editor of Radiology in November 2016. He acts as a peer-reviewer for, among other journals, Radiology and European Radiology. Celso Matos has delivered over 300 invited lectures in radiological and clinical society meetings around the world. He received the European School of Radiology Best teacher Award in 2014. He is an Honorary member of the SPRMN, SEDIA and SERAM.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

March 14, 10:00-11:30 aM CET



Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.